Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.

Hjalmar FlygtStina SöderlundJesper StentoftJohan RichterPerttu KoskenvesaSatu MustjokiWaleed MajeedAnna LübkingArta DreimaneBerit MarkevärnLeif StenkeKristina Myhr ErikssonBjørn Tore GjertsenTobias Gedde-DahlAndreja DimitrijevicLene UdbyUlla Olsson-StrömbergHenrik Hjorth-Hansen

Published in: European journal of haematology (2021)

Initial addition of PegIFN-α to DAS shows good long-term efficacy without increased toxicity.

Keyphrases

chronic myeloid leukemia
oxidative stress
open label
randomized controlled trial
clinical trial
rheumatoid arthritis
double blind
systemic lupus erythematosus
placebo controlled
oxide nanoparticles